DMUC5754A Uses, Dosage, Side Effects and more
DMUC5754A is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
| Trade Name | DMUC5754A |
| Generic | Sofituzumab vedotin |
| Sofituzumab vedotin Other Names | DMUC5754A, Sofituzumab vedotin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
